More on ACAD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $28.91 |
|
|||
| Open | $28.84 | ||||
| 52 Wk High | $42.49 | ||||
| 52 Wk Low | $16.64 | ||||
| Day High | $29.30 | ||||
| Day Low | $28.51 | ||||
| P/E | N/A | ||||
| EPS | $-0.42 | ||||
| Volume | 830,929 | ||||
- Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley
- H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Acadia Pharmaceuticals (ACAD) PT Raised to $40 at Citi
- EU approves Acadia's trofinetide for Rett syndrome treatment
- European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Acadia Pharmaceuticals (ACAD) PT Raised to $27 at Morgan Stanley
- Form 4 ACADIA PHARMACEUTICALS For: Aug 05 Filed by: Schneyer Mark C.
- Form SCHEDULE 13G ACADIA PHARMACEUTICALS Filed by: STATE STREET CORP
Entities mentioned with ACAD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Needham & Company | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
